Sophie Melicine, Laure Maucorps, Valérie Eschwège, Julie Carré, Dominique Helley, Isabelle Gouin-Thibault, Nicolas Gendron, Fabienne Nédélec-Gac, Laetitia Mauge
Contrary to direct oral anticoagulants (DOAC), unfractionated heparin (UFH) requires daily monitoring when administered at therapeutic dose. At present, UFH monitoring is preferably carried out by measuring plasma anti-Xa activity, however, in patients previously treated with an anti-Xa DOAC and switched to UFH, there is a high risk of DOAC interfering with the measurement of UFH anti-Xa activity. Residual anti-Xa DOAC in the sample can lead to an overestimation of the anticoagulant activity attributed to heparin and thus to incorrect anticoagulation. This risk of interference should not be overlooked because interference may occur even at concentration of DOAC below the hemostatic safety threshold and can last several days. To overcome this issue, several alternatives are being studied. This note provides an update on anti-Xa DOAC interference and different strategies available in current practice. It also underlines the importance of communication between biologists and clinicians on anticoagulant treatments received by patients.
与直接口服抗凝血剂(DOAC)相反,如果按治疗剂量给药,则需要每天对未分离肝素(UFH)进行监测。目前,UFH 监测最好是通过测量血浆抗 Xa 活性来进行,但是,对于之前接受过抗 Xa DOAC 治疗而转用 UFH 的患者,DOAC 很有可能干扰 UFH 抗 Xa 活性的测量。样本中残留的抗 Xa DOAC 会导致高估肝素的抗凝活性,从而导致错误的抗凝治疗。这种干扰风险不容忽视,因为即使 DOAC 的浓度低于止血安全阈值,干扰也可能发生,并可持续数天。为了解决这一问题,目前正在研究几种替代方案。本说明介绍了抗 Xa DOAC 干扰的最新情况以及当前实践中可用的不同策略。它还强调了生物学家与临床医生就患者接受的抗凝治疗进行沟通的重要性。
{"title":"[Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].","authors":"Sophie Melicine, Laure Maucorps, Valérie Eschwège, Julie Carré, Dominique Helley, Isabelle Gouin-Thibault, Nicolas Gendron, Fabienne Nédélec-Gac, Laetitia Mauge","doi":"10.1684/abc.2024.1873","DOIUrl":"10.1684/abc.2024.1873","url":null,"abstract":"<p><p>Contrary to direct oral anticoagulants (DOAC), unfractionated heparin (UFH) requires daily monitoring when administered at therapeutic dose. At present, UFH monitoring is preferably carried out by measuring plasma anti-Xa activity, however, in patients previously treated with an anti-Xa DOAC and switched to UFH, there is a high risk of DOAC interfering with the measurement of UFH anti-Xa activity. Residual anti-Xa DOAC in the sample can lead to an overestimation of the anticoagulant activity attributed to heparin and thus to incorrect anticoagulation. This risk of interference should not be overlooked because interference may occur even at concentration of DOAC below the hemostatic safety threshold and can last several days. To overcome this issue, several alternatives are being studied. This note provides an update on anti-Xa DOAC interference and different strategies available in current practice. It also underlines the importance of communication between biologists and clinicians on anticoagulant treatments received by patients.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"129-138"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141238940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The first orientation test for proteinuria typing is electrophoresis. However, this technique has several drawbacks, such as delayed turnaround time and subjective readings. Some laboratories therefore use quantitative assays of glomerular markers combined with tubular markers. However, the cost of reagents and the instability of certain markers are significant drawbacks for some peripheral laboratories. The aim of this study is to evaluate the implementation of an algorithm based on parameters that can be used by all laboratories for proteinuria typing within a timeframe compatible with the urgency of the situation. Albuminuria and urinary IgG were determined on 161 urines. ROC curves were produced, using urine electrophoresis read by an expert center as the reference method. The decision thresholds used are: glomerular proteinuria is defined by a Albumin+IgGproteinsratio greater than 75.4% (100% specificity), and tubular or overload proteinuria is defined by by a Albuminproteinsratio less than 37.3% (100% sensitivity). Agreement between the results of the algorithm selected and the reference method used in our study was 88 %, with a kappa value of 0.807 (95% CI [0.729 to 0.885]). The algorithm's performance suggests that it can find its place in the diagnostic strategy for clinically significant proteinuria, despite its limited indications. It is up to each biologist to assess the value of this algorithm in relation to the recruitment, habits and needs of clinicians.
{"title":"[Evaluation of an algorithm based on quantitative assays of glomerular parameters (albuminuria and urinary IgG) for proteinuria typing].","authors":"Ihsane Benlyamani, Nathalie Rousseau, Christine Lombard, Emmanuel Villar, Matthieu Pecquet","doi":"10.1684/abc.2024.1887","DOIUrl":"10.1684/abc.2024.1887","url":null,"abstract":"<p><p>The first orientation test for proteinuria typing is electrophoresis. However, this technique has several drawbacks, such as delayed turnaround time and subjective readings. Some laboratories therefore use quantitative assays of glomerular markers combined with tubular markers. However, the cost of reagents and the instability of certain markers are significant drawbacks for some peripheral laboratories. The aim of this study is to evaluate the implementation of an algorithm based on parameters that can be used by all laboratories for proteinuria typing within a timeframe compatible with the urgency of the situation. Albuminuria and urinary IgG were determined on 161 urines. ROC curves were produced, using urine electrophoresis read by an expert center as the reference method. The decision thresholds used are: glomerular proteinuria is defined by a Albumin+IgGproteinsratio greater than 75.4% (100% specificity), and tubular or overload proteinuria is defined by by a Albuminproteinsratio less than 37.3% (100% sensitivity). Agreement between the results of the algorithm selected and the reference method used in our study was 88 %, with a kappa value of 0.807 (95% CI [0.729 to 0.885]). The algorithm's performance suggests that it can find its place in the diagnostic strategy for clinically significant proteinuria, despite its limited indications. It is up to each biologist to assess the value of this algorithm in relation to the recruitment, habits and needs of clinicians.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"201-213"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guillaume Bachelot, Anna Ly, Diane Rivet-Danon, Nathalie Sermondade, Valentine Frydman, Antonin Lamazière, Rahaf Haj Hamid, Rachel Levy, Charlotte Dupont
Azoospermia, defined as the absence of sperm in the semen, is found in 10-15 % of infertile patients. Two-thirds of these cases are caused by impaired spermatogenesis, known as non-obstructive azoospermia (NOA). In this context, surgical sperm extraction using testicular sperm extraction (TESE) is the best option and can be offered to patients as part of fertility preservation, or to benefit from in vitro fertilization. The aim of the preoperative assessment is to identify the cause of NOA and evaluate the status of spermatogenesis. Its capacity to predict TESE success remains limited. As a result, no objective and reliable criteria are currently available to guide professionals on the chances of success and enable them to correctly assess the benefit-risk balance of this procedure. Artificial intelligence (AI), a field of research that has been rapidly expanding in recent years, has the potential to revolutionize medicine by making it more predictive and personalized. The aim of this review is to introduce AI and its key concepts, and then to examine the current state of research into predicting the success of TESE.
{"title":"[Artificial intelligence: to a better predictive strategy for testicular sperm extraction outcome in azoospermia].","authors":"Guillaume Bachelot, Anna Ly, Diane Rivet-Danon, Nathalie Sermondade, Valentine Frydman, Antonin Lamazière, Rahaf Haj Hamid, Rachel Levy, Charlotte Dupont","doi":"10.1684/abc.2024.1882","DOIUrl":"10.1684/abc.2024.1882","url":null,"abstract":"<p><p>Azoospermia, defined as the absence of sperm in the semen, is found in 10-15 % of infertile patients. Two-thirds of these cases are caused by impaired spermatogenesis, known as non-obstructive azoospermia (NOA). In this context, surgical sperm extraction using testicular sperm extraction (TESE) is the best option and can be offered to patients as part of fertility preservation, or to benefit from in vitro fertilization. The aim of the preoperative assessment is to identify the cause of NOA and evaluate the status of spermatogenesis. Its capacity to predict TESE success remains limited. As a result, no objective and reliable criteria are currently available to guide professionals on the chances of success and enable them to correctly assess the benefit-risk balance of this procedure. Artificial intelligence (AI), a field of research that has been rapidly expanding in recent years, has the potential to revolutionize medicine by making it more predictive and personalized. The aim of this review is to introduce AI and its key concepts, and then to examine the current state of research into predicting the success of TESE.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"139-149"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The incidence of pneumonia has become increasingly prevalent, and its severity has been continuously escalating, bringing significant damage and stress to people's lives. The regulatory role of RP11-773H22.4 in the onset and development of severe pneumonia is emerging as an important factor, however, the exact mechanisms controlling its effects have not been fully elucidated. ROC curve and Kaplan-Meier curve were employed to assess the diagnostic and prognostic significance of RP11-773H22.4 in severe pneumonia. qRT-PCR was employed to assess the RP11-773H22.4 and miR-1287-5p expression. The CCK-8 was employed to assess cell viability. The rate of apoptosis was measured utilizing flow cytometric. The concentration of inflammatory factors was detected by ELISA kit. The interaction between RP11-773H22.4 and miR-1287-5p was verified by dual luciferase reporter gene assay. In individuals afflicted with severe pneumonia, there was an observed up-regulation in RP11-773H22.4 expression and a corresponding decline in miR-1287-5p expression. RP11-773H22.4 demonstrated diagnostic and prognostic significance for severe pneumonia. RP11-773H22.4 augmented the viability of MRC-5 cells with LPS treatment by modulating miR-1287-5p, leading to a reduction in apoptosis and lower levels of inflammatory cytokines. RP11-773H22.4 was highly expressed in severe pneumonia and may serve as a diagnostic and prognostic marker for severe pneumonia. miR-1287-5p was downregulated in severe pneumonia, and RP11-773H22.4 participated in the pathogenesis of severe pneumonia by regulating the expression of miR-1287-5p.
{"title":"LncRNA RP11-773H22.4 is upregulated in severe pneumonia and may be a diagnostic and prognostic marker for severe pneumonia.","authors":"Yan Cao, Feiyan Wang","doi":"10.1684/abc.2024.1886","DOIUrl":"10.1684/abc.2024.1886","url":null,"abstract":"<p><p>The incidence of pneumonia has become increasingly prevalent, and its severity has been continuously escalating, bringing significant damage and stress to people's lives. The regulatory role of RP11-773H22.4 in the onset and development of severe pneumonia is emerging as an important factor, however, the exact mechanisms controlling its effects have not been fully elucidated. ROC curve and Kaplan-Meier curve were employed to assess the diagnostic and prognostic significance of RP11-773H22.4 in severe pneumonia. qRT-PCR was employed to assess the RP11-773H22.4 and miR-1287-5p expression. The CCK-8 was employed to assess cell viability. The rate of apoptosis was measured utilizing flow cytometric. The concentration of inflammatory factors was detected by ELISA kit. The interaction between RP11-773H22.4 and miR-1287-5p was verified by dual luciferase reporter gene assay. In individuals afflicted with severe pneumonia, there was an observed up-regulation in RP11-773H22.4 expression and a corresponding decline in miR-1287-5p expression. RP11-773H22.4 demonstrated diagnostic and prognostic significance for severe pneumonia. RP11-773H22.4 augmented the viability of MRC-5 cells with LPS treatment by modulating miR-1287-5p, leading to a reduction in apoptosis and lower levels of inflammatory cytokines. RP11-773H22.4 was highly expressed in severe pneumonia and may serve as a diagnostic and prognostic marker for severe pneumonia. miR-1287-5p was downregulated in severe pneumonia, and RP11-773H22.4 participated in the pathogenesis of severe pneumonia by regulating the expression of miR-1287-5p.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"187-199"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140871702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Youssef Mouraouakkil, Radia Mounir, Mina Ait El Cadi, Jamal Lamsaouri, Yassir Bousliman, Rachid ElJaoudi
Synthetic cannabinoids (CS), or synthetic endocannabinoid receptor agonists, were initially synthesized for basic research into exocannabinoid signaling pathways, as well as in clinical research for their analgesic properties. The use of CS for recreational purposes is a recent phenomenon, but one that has grown very quickly in recent years, since these molecules now represent the main category of new synthetic products (NPS). This literature review aims to bring together current data regarding the use and effects caused by CS in humans. The relationship between the structure and activity of these CSs, the pharmacology and adverse effects of these CSs and finally the different methods of analyzing CSs. A better understanding of this phenomenon is essential to raise awareness among stakeholders in the health field.
{"title":"[Toxicology of synthetic cannabinoids].","authors":"Youssef Mouraouakkil, Radia Mounir, Mina Ait El Cadi, Jamal Lamsaouri, Yassir Bousliman, Rachid ElJaoudi","doi":"10.1684/abc.2024.1888","DOIUrl":"10.1684/abc.2024.1888","url":null,"abstract":"<p><p>Synthetic cannabinoids (CS), or synthetic endocannabinoid receptor agonists, were initially synthesized for basic research into exocannabinoid signaling pathways, as well as in clinical research for their analgesic properties. The use of CS for recreational purposes is a recent phenomenon, but one that has grown very quickly in recent years, since these molecules now represent the main category of new synthetic products (NPS). This literature review aims to bring together current data regarding the use and effects caused by CS in humans. The relationship between the structure and activity of these CSs, the pharmacology and adverse effects of these CSs and finally the different methods of analyzing CSs. A better understanding of this phenomenon is essential to raise awareness among stakeholders in the health field.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 2","pages":"151-173"},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140892268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Professor Philippe Gillery honoured at WorldLab Dubai (UAE) with the IFCC Howard Morris 2024 Prize].","authors":"Bernard Gouget, Katell Peoc'h","doi":"10.1684/abc.2024.1894","DOIUrl":"https://doi.org/10.1684/abc.2024.1894","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 3","pages":"249-251"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bernard Gouget, Delphine Collin-Chavagnac, Katell Peoc'h
{"title":"[Dr David Barthelemy, winner of the IFCC Gérard Siest Prize awarded at the WorldLab Congress, Dubai 2024].","authors":"Bernard Gouget, Delphine Collin-Chavagnac, Katell Peoc'h","doi":"10.1684/abc.2024.1901","DOIUrl":"https://doi.org/10.1684/abc.2024.1901","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 3","pages":"252-253"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bryan Zamorano, Yolla Sakr, Frédérique Galopin-Dubois
The use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.
{"title":"[Evaluation of a new portable analyzer, HemoCue<sup>®</sup> Hb801, for hemoglobin point-of-care testing].","authors":"Bryan Zamorano, Yolla Sakr, Frédérique Galopin-Dubois","doi":"10.1684/abc.2024.1868","DOIUrl":"https://doi.org/10.1684/abc.2024.1868","url":null,"abstract":"<p><p>The use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"103-111"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140862239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ferroptosis is an iron dependent cell death driven by lipid peroxidation. Over the past decade, increasing evidence has confirmed that ferroptosis plays an irreplaceable role in the occurrence and development of many diseases, including various cancers, neurodegenerative diseases, cardiovascular diseases and autoimmune diseases. Autoimmune disease is an inflammatory disease characterized by the breakdown of immune tolerance. Nowadays, accumulating evidence indicates that ferroptosis is closely related to the pathogenesis of autoimmune diseases. Therefore, this review briefly introduced the mechanism of ferroptosis, and focused on the related research of ferroptosis in multiple autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), ankylosing spondylitis (AS). In addition, we also presented the idea of targeting ferroptosis as a potential therapeutic target for patients with autoimmune diseases, which may provide a direction for the development of new therapeutic strategies.
{"title":"Programmed cell death in autoimmune diseases: ferroptosis.","authors":"Jiantao Sun, Lujuan Huang, Jiawei Wang, Yelang Hu, Wenmin Wang, Haihong Zhu","doi":"10.1684/abc.2024.1866","DOIUrl":"https://doi.org/10.1684/abc.2024.1866","url":null,"abstract":"<p><p>Ferroptosis is an iron dependent cell death driven by lipid peroxidation. Over the past decade, increasing evidence has confirmed that ferroptosis plays an irreplaceable role in the occurrence and development of many diseases, including various cancers, neurodegenerative diseases, cardiovascular diseases and autoimmune diseases. Autoimmune disease is an inflammatory disease characterized by the breakdown of immune tolerance. Nowadays, accumulating evidence indicates that ferroptosis is closely related to the pathogenesis of autoimmune diseases. Therefore, this review briefly introduced the mechanism of ferroptosis, and focused on the related research of ferroptosis in multiple autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), ankylosing spondylitis (AS). In addition, we also presented the idea of targeting ferroptosis as a potential therapeutic target for patients with autoimmune diseases, which may provide a direction for the development of new therapeutic strategies.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"33-42"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140868395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[2024, a year of openness].","authors":"Katell Peoc'h","doi":"10.1684/abc.2024.1872","DOIUrl":"https://doi.org/10.1684/abc.2024.1872","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}